Novo Nordisk CEO Hopes Tresiba Can Re-Enter Germany On A Higher Price
Executive Summary
But Novo Nordisk CEO says a DEVOTE-based efficacy price review in Germany analyzing patient sub-groups 'will be a lengthy process'.
You may also be interested in...
Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE
Novo Nordisk's Tresiba reduced the risk of severe hypoglycemia in type 2 diabetes by 40% compared to Sanofi's standard-of-care insulin Lantus. The data may convince physicians to prescribe longer acting insulins, but their effect on formulary positioning remains to be seen.
What will become of the German antidiabetics market?
Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.